Share this NATF page   

New and Future Research                                                         

NATF strives to share and highlight the latest research being conducted to better understand thrombosis and its related issues.

  • The DAWN Trial
    At the 3rd annual European Stroke Organization Conference the results of the DAWN Trial were presented. The results suggest that an endovascular thromboectomy can reduce a stroke patient’s risk of becoming disabled up to 24 hours after the stroke. See More

  • Rivaroxaban Overtakes Asprin In Reducing Recurrent VTE
    Rivaroxaban has been found to be more efficient than asprin in reducing recurrent venous thromboembolism events, according to recently released results from the EINSTEIN CHOICE trial, published in the New England Journal of Medicine and presented at the American College of Cardiology’s 66th Annual Scientific Session & Expo. See More 
  • New Research Explores Gender and VTE
    New research, led by Dr. Tzoran from the Department of Internal Medicine, Rambam Health Care Campus in Haifa, Israel, is looking to compare patients with venous thromboembolism and factor V Leiden (FLV) or prothrombin 20210G-A mutation (PTM) based on their gender. See More

  • The ATTRACT Trial
    The Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) trial is designed to test how effective pharmacomechanical catheter-directed thrombolysis (PCDT) is at preventing post-thrombotic syndrome. See More

  • The Power of Statins
    In addition to helping patients with health issues related to high cholesterol statins may also help guard against venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). See more

  • The Angel Catheter: An Important New Tool in The Fight Against Pulmonary Embolism
    The Angel Catheter is a unique tool that brings healthcare providers a new option for patients who cannot be anticoagulated and are at risk for developing a pulmonary embolism. See more

  • Device Profile: The Watchman Device
    Called a “replacement for blood thinners,” what is the Watchman device and how does it work? See more

  • Thrombosis in Psoriasis Patients: The Connection to IL-6
    While it is known that psoriasis patients are at a greater risk to experience thrombosis, researchers are exploring the “why?” A new study may just hold the answer. See more

About NATF

Patients

Professionals

Events


Membership

Giving to NATF

North American Thrombosis Forum
368 Boylston Street
Brookline, MA 02445

617 - 730 - 4120


NATF is a 501(c) nonprofit

Contact Us

© 2012 North American Thrombosis Forum


Web Development by MTC